

Table 2: Daily warfarin dose and clinical characteristics in patients with various *CYP2C9**2 genotypes.

	Wild Type (1) (CC)	Heterozygous (2) (CT)	Homozygous (3) (TT)		
	Mean \pm SD median (25th-75th)	Mean \pm SD median (25th-75th)	Mean \pm SD median (25th-75th)	p Value	Multiple Comparison
Age	63.12 \pm 12.06 64.5 (55.25-72.75)	67.04 \pm 9.63 67 (61-77)	68.83 \pm 10.92 70 (58.75-80)	0.261 ^b	-
Dose	4.27 \pm 1.63 3.93 (2.5-5.36)	4.04 \pm 1.38 3.93 (3.21-5)	2.7 \pm 1.17 2.5 (1.88-3.12)	0.034 ^b	1-3
BMI (kg/m ²)	26.15 \pm 4.60 25.13 (23.33-27.69)	24.66 \pm 3.28 23.80 (22.28-25.74)	24.92 \pm 2.59 23.64 (22.99-27.93)	0.336 ^b	-
INR	2.38 \pm 0.67 2.38 (2.03-2.78)	2.50 \pm 0.80 2.51 (2.09-2.69)	2.54 \pm 0.77 2.52 (2.13-3.12)	0.544 ^b	-
Sex ^c	number (%)	number (%)	number (%)		
Female	43 (71.7%)	13 (21.7%)	4 (6.7 %)	0.899	
Male	29 (70.7%)	10 (24.4%)	2 (4.9%)		

SD: standard deviation, *CYP2C9**2: cytochrome P450 2C9*2 genotype, *a*: one-way analysis of variance, *b*: Kruskal-Wallis Test, *c*: Chi-square test for sex, *: $p \leq 0.05$.